Skip to main content

Anna Sánchez Corral

Institutions of which they are part

Predoctoral researcher
Shock, Organ Dysfunction and Resuscitation
Vall Hebron Institut de Recerca

Anna Sánchez Corral

Institutions of which they are part

Predoctoral researcher
Shock, Organ Dysfunction and Resuscitation
Vall Hebron Institut de Recerca

Research lines

Neurocritical pathology

The research line in neurocritical pathology research line, led by Dr. A. Sanchez, studies HSA and specifically its evolutionary complications such as the development of late ischemic neurological deficit and myocardial dysfunction. Refractory epileptic status and delirium are also areas of interest. This line has an ongoing thesis (Dr. M. Santafé).


IP: Anna Sánchez Corral

Projects

ESTUDIO DE BIOMARCADORES RELACIONADOS CON EPILEPSIA EN LA HEMORRAGIA SUBARACNOIDEA

IP: Laura Abraira Del Fresno
Collaborators: Anna Penalba Morenilla, Manuel Toledo Argany, Anna Sánchez Corral, Elena Fonseca Hernandez, Sofia Lallana Serrano, Estevo Santamarina Pérez, Manuel Quintana Luque
Funding agency: Fundación Eugenio Rodríguez Pascual
Funding: 24990
Reference: FERP-2022-FERP-2022-1
Duration: 01/01/2023 - 31/12/2024

Shock, Disfunció Orgànica i Ressucitació

IP: Ricard Ferrer Roca
Collaborators: César Laborda Soriano, Alejandra García Roche, Candido Diaz Lagares, Rosa Maria Gracia Gozalo, Rosa Alcaraz Peñarrocha, Juan Carlos Ruiz Rodriguez, Xavier Nuvials Casals, Judith Sacanell Lacasa, Marcos Pérez Carrasco, José Alonso Fajardo, Adolfo Ruiz Sanmartin, Óscar Mula Castellón, Anna Sánchez Corral, Elisabeth Papiol Gallofré, Luis silvestre Chiscano Camon, Eduard Argudo Serra, Maria Martinez Martinez, Jordi Riera del Brío, Raquel Albertos Martell, Noemí Varga , Sofia Contreras Medina, Andres Francisco Pacheco Reyes, Manuel Roberto Sosa Garay, Camilo andres Bonilla Rojas, Manuel Roberto Sosa Garay
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 0.01
Reference: 2021 SGR 00798
Duration: 01/01/2022 - 30/06/2025

Incremento de la liberación de combinaciones de antimicrobianos nebulizados mediante nanotecnología en el modelo murino de infección respiratoria por P.aeruginosa multiresistente. Proyecto Nanoneb-Par

IP: Joan Gavaldà Santapau
Collaborators: Antonio Moreno Galdó, Albert Pahissa Berga, Anna Sánchez Corral
Funding agency: Instituto de Salud Carlos III
Funding: 181681.5
Reference: PI13/02551
Duration: 01/01/2014 - 30/06/2017

Sistema para la gestión de los datos clínicos de pacientes con Sepsis (SEPSISNET)

IP: Juan Carlos Ruiz Rodriguez
Collaborators: Adolfo Ruiz Sanmartin, Anna Sánchez Corral, Jessica Souto Higueras, Jordi Riera del Brío, Fernando Clau Terré
Funding agency: Ministerio de Industria, Turismo y Comercio
Funding: 146817
Reference: TSI-020100-2009-204
Duration: 01/01/2010 - 31/12/2011

Related news

The study will be conducted in the Intensive Care Medicine Service of the Vall d’Hebron University Hospital and will validate the prognostic value of the NLRP3 biomarker.

SOFA-2 is being updated after thirty years to incorporate advances in diagnosis, monitoring and life support.

On European Antibiotic Awareness Day, we highlight the importance of using these medications responsibly and finding innovative solutions to combat this issue.

Related professionals

Joaquin Lopez Soriano

Joaquin Lopez Soriano

P Management and Admin. Project manager
Clinical Trials Management Unit
Clinical Research Development Directorate
Read more
Júlia Comulada Ferrer

Júlia Comulada Ferrer

Research technician
Clinical Neuroimmunology
Read more
José Antonio Arranz  Amo

José Antonio Arranz Amo

Postdoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
CINTHYA FLORES LAMAS

CINTHYA FLORES LAMAS

Medium Grade Technician
Clinical Trials Management Unit
Clinical Research Development Directorate
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.